Table 2
CHD markers in the new GMS contract
| CHD marker | No. of points available | Audit standard* |
|---|---|---|
| *Figures in brackets are those from author’s practice, December 2004. | ||
| †Before start of annual flu immunisation programme. | ||
| ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CHD, coronary heart disease; GMS, General Medical Services; LVD, left ventricular dysfunction. | ||
| Register | 6 | |
| Patients with newly diagnosed angina who are referred | 7 | 90% (100) |
| Patients with record of smoking | 7 | 90% (89) |
| Patients who have been offered smoking cessation advice | 4 | 90% (93) |
| Patients with record of BP | 7 | 90% (96) |
| Patients with BP <150/90 mm Hg | 19 | 70% (78) |
| Patients with record of cholesterol | 7 | 90% (85) |
| Patients with total cholesterol <5 mmol/l | 16 | 60% (69) |
| Patients on antiplatelet treatment or anticoagulant | 7 | 90% (91) |
| Patients on β blocker | 7 | 50% (58) |
| Patients on ACE inhibitor post-MI | 7 | 70% (93) |
| Patients with influenza immunisation | 7 | 85% (0)† |
| Register of patients with CHD and LVD | 4 | – |
| CHD and LVD confirmed by echocardiogram | 6 | 90% (100) |
| CHD and LVD patients treated with ACE inhibitors or ARB | 10 | 70% (95) |
